Great West Life Assurance Co. Can increased its position in shares of Stryker Co. (NYSE:SYK) by 19.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 369,810 shares of the medical technology company’s stock after buying an additional 60,471 shares during the period. Great West Life Assurance Co. Can owned 0.10% of Stryker worth $51,252,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Bollard Group LLC raised its position in shares of Stryker by 0.4% in the second quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after buying an additional 3 shares during the period. Baystate Wealth Management LLC raised its position in shares of Stryker by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock worth $139,000 after buying an additional 22 shares during the period. James Investment Research Inc. bought a new position in shares of Stryker during the second quarter worth $155,000. Guardian Life Insurance Co. of America raised its position in shares of Stryker by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock worth $158,000 after buying an additional 9 shares during the period. Finally, Assetmark Inc. raised its position in shares of Stryker by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock worth $168,000 after buying an additional 4 shares during the period. Institutional investors own 74.16% of the company’s stock.

Shares of Stryker Co. (NYSE SYK) opened at 139.41 on Wednesday. Stryker Co. has a 52-week low of $106.48 and a 52-week high of $148.84. The stock has a 50 day moving average of $144.80 and a 200 day moving average of $137.03. The company has a market cap of $52.15 billion, a P/E ratio of 31.12 and a beta of 0.80.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.51 by $0.02. The company had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.98 billion. Stryker had a net margin of 12.98% and a return on equity of 15.89%. Stryker’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.39 earnings per share. On average, equities analysts anticipate that Stryker Co. will post $6.47 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be given a $0.425 dividend. The ex-dividend date is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.22%. Stryker’s payout ratio is presently 37.95%.

COPYRIGHT VIOLATION NOTICE: “Stryker Co. (SYK) Shares Bought by Great West Life Assurance Co. Can” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/30/stryker-co-syk-shares-bought-by-great-west-life-assurance-co-can.html.

A number of equities analysts have weighed in on the stock. Stifel Nicolaus lifted their price target on shares of Stryker from $151.00 to $158.00 and gave the company a “buy” rating in a report on Friday, July 28th. BidaskClub lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Goldman Sachs Group, Inc. (The) started coverage on shares of Stryker in a report on Tuesday, May 16th. They set a “neutral” rating and a $129.00 target price on the stock. Canaccord Genuity restated a “buy” rating and set a $155.00 target price (down previously from $158.00) on shares of Stryker in a report on Thursday, August 24th. Finally, Argus restated a “buy” rating and set a $160.00 target price on shares of Stryker in a report on Tuesday. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $145.73.

In other news, insider David Floyd sold 7,381 shares of the business’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $144.70, for a total value of $1,068,030.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the sale, the insider now directly owns 88,207 shares of the company’s stock, valued at approximately $12,909,976.52. The disclosure for this sale can be found here. In the last three months, insiders sold 32,810 shares of company stock valued at $4,754,958. 7.40% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Stock Ratings for Stryker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Co. and related stocks with our FREE daily email newsletter.